Effect of antidepressants use in pregnancy on foetus development and adverse effects in newborns.
Over the last few years, several reports on the safety of antidepressants use in pregnancy have been published. Studies concerning the adverse effects of exposure to selective serotonin reuptake inhibitors (SSRI) during pregnancy on the developing foetus have indicated an increased risk of various congenital malformations and untoward effects such as poor neonatal adaptation syndrome or persistent pulmonary hypertension, but there still remain inconsistencies between various study results. This paper aims at reviewing the literature on the risks of exposure to antidepressants during pregnancy. SSRIs are generally considered as first-line antidepressant treatment in pregnancy, as they are generally safe and effective. To minimize the teratogenic risks, pregnant women should receive the minimal effective dose of the medication. Depression during pregnancy must not be left untreated, and it should also be remembered that the condition may extend into the postpartum period.
Ewa
E
Bałkowiec-Iskra
Chair and Department of Experimental and Clinical Pharmacology, Medical University of Warsaw. mirdag@poczta.onet.pl.
Dagmara Maria
DM
Mirowska-Guzel
Mirosław
M
Wielgoś
D000928:Antidepressive Agents / Q000627:therapeutic use*; D000013:Congenital Abnormalities / Q000453:epidemiology*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors
adverse effect; antidepressants; foetus; newborn; pregnancy